ML753286 是一种口服活性和选择性 BCRP (抗乳腺癌蛋白) 抑制剂，IC50 为 0.6 μM。 ML753286 在啮齿动物和人类肝脏 S9 组分中具有高渗透性和低至中等清除率，并且在不同物种中都具有血浆稳定性。
ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC50 of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species[1].
ML753286 has IC50 values of >30, 0.6, and 39.0 μM for the inhibition of P-gp-, BCRP-, and OATP mediated transport, respectively[1].
ML753286 (25- or 50-mg/kg (PO); 10 or 20 mg/kg (IV); 0.083-24 hours) appears to completely inhibit Bcrp functions in rats at 25 mg/kg PO or at 20 mg/kg IV. The tmax values in plasma were 1.4, 4.0, and 4.1 hours in Bcrp KO rats, WT rats pre-administered 25-mg/kg ML753286, and WT rats pre-administered 50-mg/kg ML753286, respectively[1]. Animal Model: Male Bcrp KO (Abcg2-/-) and WT (Wistar) Rats[1]
[1]. Liao M, et al. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novelselective inhibitor of breast cancer resistance protein (BCRP). Xenobiotica. 2018 May;48(5):467-477.
动态评分
0.0